Mitoxantrone therapy in rapidly worsening multiple sclerosis

BENEŠOVÁ, Yvonne, Pavel ŠTOURAČ, M. BERÁNEK and Zdeněk KADAŇKA. Mitoxantrone therapy in rapidly worsening multiple sclerosis. Bratislavské lekárske listy. Bratislava: LF UK, 2005, vol. 106, No 3, p. 141-143. ISSN 0006-9248.

Basic information

• Original name: Mitoxantrone therapy in rapidly worsening multiple sclerosis
• Name in Czech: Léčba mitoxantronem u rychle progredující roztroušené sklerózy
• Authors: BENEŠOVÁ, Yvonne (203 Czech Republic), Pavel ŠTOURAČ (203 Czech Republic, guarantor), M. BERÁNEK (203 Czech Republic) and Zdeněk KADAŇKA (203 Czech Republic).
• Edition: Bratislavské lekárske listy, Bratislava, LF UK, 2005, 0006-9248.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30000 3. Medical and Health Sciences
• Country of publisher: Slovakia
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/05:00014829
• Organization unit: Faculty of Medicine
• Keywords in English: multiple sclerosis; immunotherapy; mitoxantrone; EDSS
• Tags: EDSS, Immunotherapy, mitoxantrone, Multiple sclerosis
• Tags: Reviewed

Abstract

The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evaluated. Nonparametric Wilcoxon matched pair test was used for statistical analysis.

Abstract (in Czech)

Cílem studie bylo zhodnotit efekt a bezpečnost léčby mitoxantronem (MX) u nemocných s relabující a sekundárně progresivní roztroušenou sklerózou (RS). Bylo sledováno 33 pacientů (10 mužů, 23 žen, o průměrném věku 48,5+/- 9,9 let), neschopnost byla hodnocena pomocí Expanded Disability Status Scale (EDSS). Léčba mitoxantronem byla zavedena u nemocných, u kterých došlo během jednoho roku ke zhoršení EDSS skóre o minimálně 1 bod a nereagovali na jinou léčbu. Pacienti byli léčeni 6 pulsy mitoxantronem intravenózně každý měsíc v dávce 12 mg/m2, (celková kumulativní dávka nepřekročila 140 mg/m2) a metylprednisolonem v dávce 1000 mg. Byla zhodnocena progrese EDSS v průběhu 1 roku.

Links

• MSM0021622404, plan (intention): Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS

Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.